• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型喹诺酮类和恶唑烷酮类药物对马杜拉放线菌的体外活性

In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.

作者信息

Vera-Cabrera Lucio, Ochoa-Felix Elsa Y, Gonzalez Gloria, Tijerina Rolando, Choi Sung H, Welsh Oliverio

机构信息

Laboratorio Interdisciplinario de Investigación Dermatológica, Servicio de Dermatología, Hospital Universitario, Nuevo León, México.

出版信息

Antimicrob Agents Chemother. 2004 Mar;48(3):1037-9. doi: 10.1128/AAC.48.3.1037-1039.2004.

DOI:10.1128/AAC.48.3.1037-1039.2004
PMID:14982804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC353109/
Abstract

In this work, we studied the in vitro sensitivity of 24 strains of Actinomadura madurae to a new oxazolidinone (DA-7867), gatifloxacin, moxifloxacin, and garenoxacin by using a broth microdilution method. We observed that the A. madurae strains had a high level of sensitivity to all the antimicrobials tested. The most active drug was DA-7867, with a MIC at which 90% of the strains are inhibited (MIC(90)) of 0.125 micro g/ml and a MIC(50) of 0.06 micro g/ml.

摘要

在本研究中,我们采用肉汤微量稀释法研究了24株马杜拉放线菌对一种新型恶唑烷酮(DA - 7867)、加替沙星、莫西沙星和加雷沙星的体外敏感性。我们观察到,马杜拉放线菌菌株对所有测试抗菌药物均具有高度敏感性。活性最强的药物是DA - 7867,其90%菌株被抑制时的最低抑菌浓度(MIC(90))为0.125μg/ml,50%菌株被抑制时的最低抑菌浓度(MIC(50))为0.06μg/ml。

相似文献

1
In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae.新型喹诺酮类和恶唑烷酮类药物对马杜拉放线菌的体外活性
Antimicrob Agents Chemother. 2004 Mar;48(3):1037-9. doi: 10.1128/AAC.48.3.1037-1039.2004.
2
In vitro activities of new antimicrobials against Nocardia brasiliensis.新型抗菌药物对巴西诺卡菌的体外活性
Antimicrob Agents Chemother. 2004 Feb;48(2):602-4. doi: 10.1128/AAC.48.2.602-604.2004.
3
Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.新型去氟喹诺酮类药物加替沙星(BMS-284756)的商业肉汤微量稀释药敏板验证及重现性试验
J Clin Microbiol. 2003 Aug;41(8):3967-9. doi: 10.1128/JCM.41.8.3967-3969.2003.
4
In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.新型氟喹诺酮类药物DK-507k的体外和体内抗菌活性
Antimicrob Agents Chemother. 2003 Dec;47(12):3750-9. doi: 10.1128/AAC.47.12.3750-3759.2003.
5
In vitro activities of DA-7867, a novel oxazolidinone, against recent clinical isolates of aerobic and anaerobic bacteria.新型恶唑烷酮类药物DA-7867对近期需氧菌和厌氧菌临床分离株的体外活性
Antimicrob Agents Chemother. 2004 Jan;48(1):352-7. doi: 10.1128/AAC.48.1.352-357.2004.
6
Novel oxazolidinone-quinolone hybrid antimicrobials.新型恶唑烷酮-喹诺酮类杂合抗菌剂。
Bioorg Med Chem Lett. 2003 Dec 1;13(23):4213-6. doi: 10.1016/j.bmcl.2003.07.021.
7
Validation of a commercial dry-form broth microdilution device (Sensititre) for testing tedizolid, a new oxazolidinone.用于检测新型恶唑烷酮类药物特地唑胺的商用干式肉汤微量稀释装置(Sensititre)的验证
J Clin Microbiol. 2015 Feb;53(2):657-9. doi: 10.1128/JCM.02769-14. Epub 2014 Nov 19.
8
In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.新型喹诺酮类药物加替沙星、加替沙星和吉米沙星对人支原体的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3165-8. doi: 10.1128/AAC.48.8.3165-3168.2004.
9
Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.加替沙星(BMS - 284756)对12种革兰氏阳性或阴性菌的抗生素后效应
Antimicrob Agents Chemother. 2003 Mar;47(3):1140-2. doi: 10.1128/AAC.47.3.1140-1142.2003.
10
[Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].[加替沙星(BMS-284756)的体外活性比较。西班牙哨兵计划(1999 - 2000年)]
Enferm Infecc Microbiol Clin. 2003 Oct;21(8):404-9. doi: 10.1016/s0213-005x(03)72977-2.

引用本文的文献

1
Actinomadura welshii sp. nov., a New Mycetoma Agent in Mexico.墨西哥新发现的马杜拉放线菌新种——威尔士马杜拉放线菌,一种新的足菌肿病原体
PLoS Negl Trop Dis. 2025 Apr 11;19(4):e0013016. doi: 10.1371/journal.pntd.0013016. eCollection 2025 Apr.
2
Actinomycetoma by : Clinical Characteristics and Treatment of 47 Cases.放线菌性足菌肿:47例临床特征与治疗
Indian Dermatol Online J. 2021 Feb 22;12(2):285-289. doi: 10.4103/idoj.IDOJ_474_20. eCollection 2021 Mar-Apr.
3
Linezolid: A novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma.利奈唑胺:治疗放线菌性足菌肿无反应病例的一种新选择。
Indian J Dermatol Venereol Leprol. 2021 May-Jun;87(3):455. doi: 10.25259/IJDVL_125_20.
4
Molecular identification of Actinomadura madurae isolated from a patient originally from Algeria; observations from a case report.从一名原籍阿尔及利亚的患者中分离出的马杜拉放线菌的分子鉴定;病例报告观察。
BMC Infect Dis. 2020 Nov 11;20(1):829. doi: 10.1186/s12879-020-05552-z.
5
Therapeutic effect of a novel oxazolidinone, DA-7867, in BALB/c mice infected with Nocardia brasiliensis.新型恶唑烷酮类药物 DA-7867 对感染巴西诺卡氏菌的 BALB/c 小鼠的治疗效果。
PLoS Negl Trop Dis. 2008 Sep 10;2(9):e289. doi: 10.1371/journal.pntd.0000289.
6
Prodrugs for the treatment of neglected diseases.用于治疗被忽视疾病的前体药物。
Molecules. 2007 Mar 19;13(3):616-77. doi: 10.3390/molecules13030616.
7
In vitro activities of the novel oxazolidinones DA-7867 and DA-7157 against rapidly and slowly growing mycobacteria.新型恶唑烷酮类药物DA - 7867和DA - 7157对快速生长和缓慢生长分枝杆菌的体外活性
Antimicrob Agents Chemother. 2006 Dec;50(12):4027-9. doi: 10.1128/AAC.00763-06. Epub 2006 Oct 2.
8
In vitro activities of DA-7157 and DA-7218 against Mycobacterium tuberculosis and Nocardia brasiliensis.DA-7157和DA-7218对结核分枝杆菌和巴西诺卡菌的体外活性。
Antimicrob Agents Chemother. 2006 Sep;50(9):3170-2. doi: 10.1128/AAC.00571-06.

本文引用的文献

1
[Mycetoma: 130 cases].[足菌肿:130例]
Ann Dermatol Venereol. 2003 Jan;130(1 Pt 1):16-9.
2
Clinical experience with linezolid for the treatment of nocardia infection.利奈唑胺治疗诺卡菌感染的临床经验。
Clin Infect Dis. 2003 Feb 1;36(3):313-8. doi: 10.1086/345907. Epub 2003 Jan 13.
3
Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal.西孟加拉邦264例足菌肿回顾性研究的流行病学特征
Trop Med Int Health. 2002 Sep;7(9):788-92. doi: 10.1046/j.1365-3156.2002.00915.x.
4
In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates.
J Antimicrob Chemother. 2002 Jul;50(1):140-2. doi: 10.1093/jac/dkf081.
5
The in vitro activity of BMS-284756, a new des-fluorinated quinolone.新型去氟喹诺酮类药物BMS-284756的体外活性
J Antimicrob Chemother. 2002 Jan;49(1):177-84. doi: 10.1093/jac/49.1.177.
6
In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis.新型恶唑烷酮类抗菌药物PNU - 100766(利奈唑胺)对巴西诺卡菌的体外活性
Antimicrob Agents Chemother. 2001 Dec;45(12):3629-30. doi: 10.1128/AAC.45.12.3629-3630.2001.
7
In vitro activities of linezolid against multiple Nocardia species.利奈唑胺对多种诺卡菌属细菌的体外活性。
Antimicrob Agents Chemother. 2001 Apr;45(4):1295-7. doi: 10.1128/AAC.45.4.1295-1297.2001.
8
Linezolid.利奈唑胺
Drugs. 2000 Apr;59(4):815-27; discussion 828. doi: 10.2165/00003495-200059040-00007.
9
Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.莫西沙星对革兰氏阳性临床分离株的体外活性比较
J Antimicrob Chemother. 2000 Jan;45(1):31-9. doi: 10.1093/jac/45.1.31.
10
Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma.阿米卡星单独及联合甲氧苄啶-磺胺甲恶唑治疗放线菌性足菌肿
J Am Acad Dermatol. 1987 Sep;17(3):443-8. doi: 10.1016/s0190-9622(87)70227-8.